Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

406
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
406
Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

3.0K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
3.0K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

335
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
335
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

91
The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing...
91
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

388
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
388
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthetic biomedical data generation in support of <i>In Silico</i> Clinical Trials.

Frontiers in big data·2023
Same author

Real-Time Multi-Ion-Monitoring Front-End With Interference Compensation by Multi-Output Support Vector Regressor.

IEEE transactions on biomedical circuits and systems·2021
Same author

Continuous monitoring of propofol in human serum with fouling compensation by support vector classifier.

Biosensors & bioelectronics·2020
Same author

Reliability and reproducibility among different platforms for tumour BRCA testing in ovarian cancer: a study of the Italian NGS Network.

Journal of clinical pathology·2020
Same author

Boolean satisfiability in quantum compilation.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2019
Same author

Fast Procedures for the Electrodeposition of Platinum Nanostructures on Miniaturized Electrodes for Improved Ion Sensing.

Sensors (Basel, Switzerland)·2019

Related Experiment Video

Updated: May 7, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.2K

Parameterized SVM for personalized drug concentration prediction.

Wenqi You, Alena Simalatsar, Giovanni De Micheli

    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
    |October 11, 2013
    PubMed
    Summary

    This study introduces a novel Parameterized Support Vector Machine (ParaSVM) for modeling drug concentration curves. This approach enhances accuracy by integrating patient data and calibrating with Therapeutic Drug Monitoring (TDM) measurements.

    More Related Videos

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
    13:54

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

    Published on: August 18, 2023

    6.4K
    Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
    10:21

    Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

    Published on: February 23, 2024

    3.2K

    Related Experiment Videos

    Last Updated: May 7, 2026

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
    09:41

    An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

    Published on: July 15, 2015

    8.2K
    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
    13:54

    A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

    Published on: August 18, 2023

    6.4K
    Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
    10:21

    Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

    Published on: February 23, 2024

    3.2K

    Area of Science:

    • Pharmacometrics
    • Machine Learning in Healthcare
    • Computational Biology

    Background:

    • Accurate modeling of Drug Concentration to Time (DCT) curves is crucial for personalized medicine.
    • Existing methods may not fully leverage patient-specific features or adapt to real-world measurements.
    • Therapeutic Drug Monitoring (TDM) provides valuable data for refining pharmacokinetic models.

    Purpose of the Study:

    • To propose a novel Parameterized Support Vector Machine (ParaSVM) for robust DCT curve modeling.
    • To integrate patient features and analytical modeling for improved DCT curve approximation.
    • To enable adaptive calibration of DCT curves using TDM data.

    Main Methods:

    • Development of the Parameterized Support Vector Machine (ParaSVM) algorithm.
    • Integration of Support Vector Machine (SVM) for patient feature analysis.
    • Application of an analytical model for DCT point approximation and curve calibration.
    • Utilization of the RANSAC algorithm to build a parameter library for basis functions.

    Main Results:

    • Successful implementation of ParaSVM for constructing DCT curves.
    • Demonstrated calibration of DCT curves using TDM measurements in an imatinib case study.
    • Validation of the ParaSVM approach's ability to model and refine DCT profiles.

    Conclusions:

    • ParaSVM offers a powerful and flexible framework for DCT curve modeling.
    • The integration of SVM and analytical modeling enhances predictive accuracy.
    • ParaSVM facilitates effective curve calibration with real-world TDM data, improving therapeutic drug management.